CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
MitoTempol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06466655
NCT06466655N/ACompleted

Accelerated Vascular Aging in Midlife as a Mechanism Linking Daily Stress to Cognitive Decline

University of Delaware·interventional·Posted Jun 20, 2024·Updated Oct 2, 2025

In Brief

A clinical study evaluating MitoTempol and Lactated Ringer's (control) for Middle-aged Adults and Major Depressive Disorder. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The goal of this pilot clinical trial is to begin to understand how day-to-day stress affects cardiovascular health and brain function in middle-aged adults. The main question aims to answer is whether the link between daily stress and vascular dysfunction is a potential mechanism of increased risk for future cognitive decline. Participants will complete a 15-day testing cycle. During this cycle, participants will complete daily assessments of stress using an online survey tool for 14-consecutive days. On the last day of each cycle, vascular function will be assessed during a laboratory visit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20252026
First PostedJun 20, 2024
Enrollment StartMay 30, 2024
Primary CompletionApr 10, 2025
Study CompletionMay 29, 2025
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 2.0 years ago

Interventions

MitoTempoldrug

One intradermal microdialysis probes will be perfused with MitoTempol (0.5 mM) during a standard local skin heating protocol.

Lactated Ringer's (control)drug

One intradermal microdialysis probes will be perfused with lactated Ringer's (control) during a standard local skin heating protocol.